EUVIMEDEUVIMED entdecken
LeserbriefLeitlinieOpen Access

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022

Mariko Harada-Shiba, Hidenori Arai, Hirotoshi Ohmura, Hiroaki Okazaki, Daisuke Sugiyama, Hayato Tada, Kazushige Dobashi, Kota Matsuki, Tetsuo Minamino, Shizuya Yamashita, Koutaro Yokote

Journal of Atherosclerosis and Thrombosis · 01.05.2023 · 30 (5) · 558-586

DOI: 10.5551/jat.cr005 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.05.2023. Verfasst von Mariko Harada-Shiba und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Osaka Medical and Pharmaceutical University. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Blood Component Removal. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BQ2. What are the Prognosis and Main Complications of Patients with FH? • CAD: odds ratio 10-20 times higher than non-FH (Level of evidence: E-1a* ) • Peripheral arterial disease: odds ratio 5-10 times higher than non-FH (Level of evidence: E-1a) • Stroke: no clear impact (Level of evidence: E-1a) • Aortic valve stenosis: no epidemiological association was shown, but there have been case reports of FH complicating the disease.(Level of evidence: E-3) • Abdominal aortic aneurysm: no epidemiological association was shown, but there have been case reports of FH complicating the disease.(Level of evidence: E-3) * Although there was no meta-analysis of cohort Advance

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIBlood Component RemovalHumansAdultCholesterol, LDLHomozygoteHeterozygote

Stichwörter der Autor:innen

AdultsDiagnostic criteriaFamilial HypercholesterolemiaHeterozygoteHomozygoteLDL apheresisLifestylePharmacological therapyStatinsTreatment guidelines

Substanzen

Cholesterol, LDL

Autor:innen und Institutionen

  • Cardiovascular Center, Osaka Medical and Pharmaceutical University.
  • Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
  • National Center for Geriatrics and Gerontology.
  • Department of Cardiovascular Biology and Medicine, Juntendo University, School of Medicine.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University.
  • Faculty of Nursing And Medical Care, Keio University.

Zitieren

APA

Harada-Shiba, M., Arai, H., Ohmura, H., Okazaki, H., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., & Yokote, K. (2023). Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis, 30(5), 558-586. https://doi.org/10.5551/jat.cr005

Vancouver

Harada-Shiba M, Arai H, Ohmura H, Okazaki H, Sugiyama D, Tada H, et al. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis. 2023;30(5):558-586. doi:10.5551/jat.cr005

BibTeX
@article{HaradaShiba2023,
  author = {Harada-Shiba, Mariko and Arai, Hidenori and Ohmura, Hirotoshi and Okazaki, Hiroaki and Sugiyama, Daisuke and Tada, Hayato and Dobashi, Kazushige and Matsuki, Kota and Minamino, Tetsuo and Yamashita, Shizuya and Yokote, Koutaro},
  title = {Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2023},
  volume = {30},
  number = {5},
  pages = {558--586},
  doi = {10.5551/jat.cr005}
}
Kostenlos starten →